Which solubility-enhancing technology should I use to support my early drug development project?

Which solubility-enhancing technology should I use to support my early drug development project?

In this Ardena Insight, we address the challenge of poor aqueous solubility in early-phase drug candidates and the formulation strategies designed to overcome it. As most compounds emerging from modern pipelines show limited solubility, enhancing absorption after oral administration becomes a critical goal.

While a variety of technologies exist to improve solubility and dissolution, no universal solution applies. Formulation choices must align with the drug’s physicochemical properties, permeability and dose. In early development, priority is given to approaches that support high drug loading, simple manufacturing, and flexible administration.

Ardena offers expert guidance to help you navigate formulation decisions for poorly soluble compounds, optimizing performance while accelerating development timelines.

Read the full article here
See all
On-Demand Webinar: Nanomedicine Development from Lab to Clinic: Strategies to Overcome Scale-Up and Analytical Challenges
Webinars

On-Demand Webinar: Nanomedicine Development from Lab to Clinic: Strategies to Overcome Scale-Up and Analytical Challenges

Read more
Evolution of Stability Guidelines: From the ICH Q1A-F Series to the Consolidated ICH Q1 Guideline
Whitepapers

Evolution of Stability Guidelines: From the ICH Q1A-F Series to the Consolidated ICH Q1 Guideline

Read more
# Drug Product Drug Substance
Nitrosamine Risk Assessment According to ICH M7
Expert Q&A

Nitrosamine Risk Assessment According to ICH M7

Read more
Deciphering the Complex Characteristics of Nanomedicine
Whitepapers

Deciphering the Complex Characteristics of Nanomedicine

Read more
# Drug Substance Nanomedicine
Late-Stage Development and Manufacturing of Novel Excipients for Precision Nanomedicines and Targeted Therapies
Whitepapers

Late-Stage Development and Manufacturing of Novel Excipients for Precision Nanomedicines and Targeted Therapies

Read more
Innovations in API Manufacturing of Small Molecule Drugs
Whitepapers

Innovations in API Manufacturing of Small Molecule Drugs

Read more
# Drug Substance High potency & controlled substances
Microfluidization for Precision Nanoparticle Engineering
Expert Q&A

Microfluidization for Precision Nanoparticle Engineering

Read more
# Nanomedicine
Leading the Way in Nanomedicine Solutions
Info sheets

Leading the Way in Nanomedicine Solutions

Read more
On-demand webinar: Mastering Nanomedicines Characterization: Techniques for Determining Particle Size Distribution Based on Dynamic Light Scattering
Webinars

On-demand webinar: Mastering Nanomedicines Characterization: Techniques for Determining Particle Size Distribution Based on Dynamic Light Scattering

Read more
# Nanomedicine
Using Flow Technology in Nanoparticle Synthesis
Expert Q&A

Using Flow Technology in Nanoparticle Synthesis

Read more
# Nanomedicine
Advancing oligonucleotide therapeutics with cutting-edge bioanalytics
Info sheets

Advancing oligonucleotide therapeutics with cutting-edge bioanalytics

Read more
# Bioanalysis Nanomedicine
Fit-for-Phase Nanomedicine Solutions
Info sheets

Fit-for-Phase Nanomedicine Solutions

Read more
# Nanomedicine
Deciphering the complex characteristics of nanoparticles by asymmetric flow field-flow fractionation
Whitepapers

Deciphering the complex characteristics of nanoparticles by asymmetric flow field-flow fractionation

Read more
# Nanomedicine
Navigating the CMC Regulatory Landscape for Oligonucleotide Therapeutics
Info sheets

Navigating the CMC Regulatory Landscape for Oligonucleotide Therapeutics

Read more
# CMC Regulatory Nanomedicine

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.